Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company founded in 2017 in San Diego, California, with a singular mission rooted in redefining metabolic disease treatment through physiological restoration rather than symptomatic suppression. The company emerged from deep academic insights into innate homeostatic regulation—particularly the body’s endogenous capacity to self-correct imbalances in energy metabolism, insulin sensitivity, and lipid homeostasis. Led by a founding team of veteran scientists and drug developers with decades of experience at institutions including Genentech, Novartis, and the Salk Institute, AARD was deliberately structured as a science-first organization, prioritizing target validation grounded in human genetics and translational physiology over conventional high-throughput screening paradigms. Its incorporation coincided with growing recognition of the limitations of current metabolic therapeutics—including weight regain after GLP-1 agonist discontinuation, hepatic steatosis progression despite glycemic control, and cardiovascular risk persistence in type 2 diabetes—prompting AARD to pursue a fundamentally distinct therapeutic hypothesis: pharmacologic activation of evolutionarily conserved homeostatic circuits, such as the AMPK–SIRT1–PGC-1α axis and nuclear receptor-mediated transcriptional networks governing mitochondrial biogenesis and circadian metabolic flux. This foundational philosophy continues to inform every stage of its R&D pipeline, corporate governance, and partnership strategy.